Contact
Antineo
Retour
Antineo
Track-Record
Mission and Vision
Our team
Our scientific commitee
Animal use at Antineo
Preclinical services
Retour
Preclinical services
In vitro preclinical services
Retour
In vitro Endpoint studies
In vitro continuous-monitoring studies
Sample Characterisation
Ex vivo preclinical services
In vivo preclinical services
Preclinical development of immunotherapies
Tumour models
Retour
Tumour models
Syngeneic tumour models
Retour
Liquid tumours in Syngeneic models
Solid tumours in Syngeneic models
Cell-Derived Xenografts
Patient-Derived Xenograft
Original preclinical resistant tumour models
Our Strengths
Retour
Our Strengths
Facilities & ressources
Equipment
Networks and Partnerships
News & Events
Retour
News & Events
News
Press Release
Posters
Events
Upcoming Events
Resources
Retour
Resources
Publications
Application notes
Application Notes
White papers
Presentation Corporate 2025
Rechercher
Application Notes
Home
>
Application Notes
ANTIBODY DRUG CONJUGATES (ADCS) : TRANSFORMING TARGETED CANCER THERAPIES
TUMOR MICROENVIRONMENT COMPONENTS IN PRECLINICAL ONCOLOGY RESEARCH
TUMOR TYPES AND IMMUNE MICROENVIRONMENT
Tumor microenvironment and cancer resistance
Visit antineo.fr
Antineo
About Antineo
Track-Record
Mission and Vision
Our team
Scientific committee
Animal use at Antineo
Preclinical services
In vitro services
Endpoint studies
Continuous-monitoring
Sample Characterisation
Ex vivo services
In vivo services
Immunotherapies
Tumour models
Syngeneic models
Liquid tumours
Solid tumours
Cell-Derived Xenografts
Patient-Derived Xenograft
Original resistant models
Our Strengths
Facilities & Resources
Equipment
Networks & Partnerships
News & Resources
News & Events
Publications
Application notes
Corporate Presentation 2026
✉ Contact our team
We use cookies to guarantee you the best experience on our website
Ok
No
Privacy policy
Revoke consent
